Meme kanseri ve kronik lenfositik loseminin birlikteliği: Olgu sunumu

Certain malignancies may occur concomitantly or consecutively. . We present a female patient with breast carcinoma who had chronic leukemia concurrently with breast cancer.. She underwent a modified radical mastectomy. The histopathologic examination of both mastectomy and axillary specimen revealed diffuse, atypical lymphoid proliferation and microscopic foci of lymphocytic infiltrations beside the typical breast carcinoma findings. Lymphocytes taken from peripheral blood and bone marrow aspirates were stained with CD5 and CD20. The diagnosis of chronic lymphocytic leukemia (CLL) was confirmed. CLL was diagnosed as a synchronous malignancy together with breast carcinoma. It should be kept in mind that breast carcinoma may occur concomitantly with other malignancies especially CLL. Second malignancies occur with an increased frequency in patients with CLL, mainly because of the immune defects associated with this disease.Maligniteler aynı anda veya birbirini takiben aynı hastada görülebilir. Biz bu çalışmada kronik lösemi ile aynı anda olan meme kanseri nedeniyle modifiye radikal mastektomi yapılan bayan hastayı sunduk. Histopatolojik incelemede tipik meme kanseri bulguları yanında hem memede hem de aksiller spesmende atipik lenfoid proliferasyon ve mikroskopik lenfositik infiltrasyon odakları saptandı. Periferik kandan alınan lenfositler ve kemik iliği CD5 ve CD20 ile boyandı. Kronik lenfositik lösemi (KLL) tanısı doğrulandı. KLL, meme kanseri ile senkron malignite olarak teşhis edildi. Meme kanserinin özellikle KLL gibi diğer maligniteler ile birlikte olabileceği akılda tutulmalıdır. İkinci maligniteler, KLL hastalarında immün defekt sebebiyle daha fazla görülebilir

Meme kanseri ve kronik lenfositik loseminin birlikteliği: Olgu sunumu

Maligniteler aynı anda veya birbirini takiben aynı hastada görülebilir. Biz bu çalışmada kronik lösemi ile aynı anda olan meme kanseri nedeniyle modifiye radikal mastektomi yapılan bayan hastayı sunduk. Histopatolojik incelemede tipik meme kanseri bulguları yanında hem memede hem de aksiller spesmende atipik lenfoid proliferasyon ve mikroskopik lenfositik infiltrasyon odakları saptandı. Periferik kandan alınan lenfositler ve kemik iliği CD5 ve CD20 ile boyandı. Kronik lenfositik lösemi (KLL) tanısı doğrulandı. KLL, meme kanseri ile senkron malignite olarak teşhis edildi. Meme kanserinin özellikle KLL gibi diğer maligniteler ile birlikte olabileceği akılda tutulmalıdır. İkinci maligniteler, KLL hastalarında immün defekt sebebiyle daha fazla görülebilir.Certain malignancies may occur concomitantly or consecutively. . We present a female patient with breast carcinoma who had chronic leukemia concurrently with breast cancer.. She underwent a modified radical mastectomy. The histopathologic examination of both mastectomy and axillary specimen revealed diffuse, atypical lymphoid proliferation and microscopic foci of lymphocytic infiltrations beside the typical breast carcinoma findings. Lymphocytes taken from peripheral blood and bone marrow aspirates were stained with CD5 and CD20. The diagnosis of chronic lymphocytic leukemia (CLL) was confirmed. CLL was diagnosed as a synchronous malignancy together with breast carcinoma. It should be kept in mind that breast carcinoma may occur concomitantly with other malignancies especially CLL. Second malignancies occur with an increased frequency in patients with CLL, mainly because of the immune defects associated with this disease

In Situ Hybridization Analysis of Invasive Breast Carcinomas with Immunohistochemically Negative Her-2 Status (A National Multicenter Study)

Objective: The aim of this study was to determine the rate of Her-2 gene amplification in breast cancer cases with a previous negative Her-2 result as determined by immunohistochemistry (score 0 or 1). Material and Method: 552 cases of invasive breast carcinoma were assessed with the contribution of 9 centers. Previous immunohistochemistry score was either 0 or 1+ in all cases. These cases were re-tested by Her-2 silver in situ hybridization in the central laboratory. Her-2 gene amplification was defined as Her-2/CEP 17 ratio of more than 2.2. Cases with a ratio between 1.8 and 2.0 were defined as equivocal and cases with a ratio of less than 1.8 were defined as negative. Results: Re-testing of the 552 cases with silver in situ hybridization showed a total of 22 cases with Her-2 gene amplification, of which 11 (3.2%) were found to be score 0, and 11 were found to be score 1+ (5.3%) by immunohistochemistry previously. Her-2 gene amplification rate of cases (score 0 and 1+) ranged from 0% to 10.48% among the centers. Polysomy was found in 28 (8.1%) of the score 0 cases and 25 (12.1%) among the score 1+ cases. Five (9.4%) of the cases with polysomy were found to be amplified, and 48 (90.6%) were not. Conclusion: The results of the study show that a group of cases (3.98%) with a potential to benefit from anti-Her-2 therapy may be missed with the immunohistochemical method. This indicates the importance of quality assurance, especially in central laboratories with many breast cancer cases in daily practice

In situ hybridization analysis of invasive breast carcinomas with immunohistochemically negative her-2 status (a national multicenter study)

Objective: The aim of this study was to determine the rate of Her-2 gene amplification in breast cancer cases with a previous negative Her-2 result as determined by immunohistochemistry (score 0 or 1). Material and Method: 552 cases of invasive breast carcinoma were assessed with the contribution of 9 centers. Previous immunohistochemistry score was either 0 or 1+ in all cases. These cases were re-tested by Her-2 silver in situ hybridization in the central laboratory. Her-2 gene amplification was defined as Her-2/CEP 17 ratio of more than 2.2. Cases with a ratio between 1.8 and 2.0 were defined as equivocal and cases with a ratio of less than 1.8 were defined as negative. Results: Re-testing of the 552 cases with silver in situ hybridization showed a total of 22 cases with Her-2 gene amplification, of which 11 (3.2%) were found to be score 0, and 11 were found to be score 1+ (5.3%) by immunohistochemistry previously. Her-2 gene amplification rate of cases (score 0 and 1+) ranged from 0% to 10.48% among the centers. Polysomy was found in 28 (8.1%) of the score 0 cases and 25 (12.1%) among the score 1+ cases. Five (9.4%) of the cases with polysomy were found to be amplified, and 48 (90.6%) were not. Conclusion: The results of the study show that a group of cases (3.98%) with a potential to benefit from anti-Her-2 therapy may be missed with the immunohistochemical method. This indicates the importance of quality assurance, especially in central laboratories with many breast cancer cases in daily practice